Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    Invectys
Previous Study | Return to List | Next Study

Invac-1 in Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03265717
Recruitment Status : Recruiting
First Posted : August 29, 2017
Last Update Posted : July 27, 2018
Sponsor:
Information provided by (Responsible Party):
Invectys

Brief Summary:

Phase 2 study to assess the efficacy of INVAC-1 at a dose of 800 µg for 6 cycles 4 weeks apart on Minimal Residual Disease (MRD) eradication rate in the bone marrow, either as a single agent in a high risk "watch and wait" group (group 1 - 42 patients) or in combination with ibrutinib (group 2 - 42 patients), in patients with Chronic Lymphocytic Leukemia (CLL).

Pharmacodynamics and safety will also be assessed.


Condition or disease Intervention/treatment Phase
Leukemia, Lymphocytic, Chronic, B-Cell Biological: INVAC-1 Phase 2

Detailed Description:

The study will be a phase II, open label, single-arm trial of INVAC-1 at a dose of 800 µg in patients with CLL.

The primary goal of the study is to achieve MRD negativity in each group. 42 patients are to be included in each study group.

Group 1: Untreated high risk "watch and wait" Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MD Anderson Cancer Center nomogram criteria). Patients will be treated by INVAC-1 for 6 doses at 4-week intervals and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.

Group 2: Ibrutinib treated patients Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
Actual Study Start Date : July 25, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : March 2022


Arm Intervention/treatment
Experimental: Group 1: Untreated high risk "watch and wait"
Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
Biological: INVAC-1
Patients are treated by INVAC-1 for 6 cycles at 4-week intervals

Experimental: Group 2: Ibrutinib treated patients
Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
Biological: INVAC-1
Patients are treated by INVAC-1 for 6 cycles at 4-week intervals




Primary Outcome Measures :
  1. Minimal Residual Disease (MRD) eradication rate in the bone marrow [ Time Frame: 6 months ]
    MRD eradication rate (by standardized 4-color flow cytometry, with a limit of detection of 0.01% CLL cells among total leucocytes in the bone marrow after 6 monthly injections of INVAC-1


Secondary Outcome Measures :
  1. MRD eradication rate in blood after 6 monthly injections of INVAC-1 [ Time Frame: 6 months ]
  2. Duration of MRD eradication in bone marrow and blood [ Time Frame: approximately 3 years ]
  3. Cumulative incidence of partial and complete response by IWCLL 2008 [ Time Frame: every 6 months for 3 years ]
  4. PFS as assessed by investigators according to IWCLL 2008 criteria [ Time Frame: approximately 3 years ]
  5. Time to next CLL treatment [ Time Frame: approximately 3 years ]
  6. Overall survival [ Time Frame: approximately 3 years ]
  7. Adverse events [ Time Frame: up to 7 months ]
    type, frequency, severity as graded by NCI CTCAE v.4.03

  8. Cellular (CD4 & CD8) specific anti hTert response by FACS including cytokine polarization Th1, Th2, Th17 [ Time Frame: every 6 months for 3 years ]
  9. Count of blood circulating CD4, CD8, Treg, NK cells [ Time Frame: every 6 months for 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Group 1: Untreated high risk "watch and wait"

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Rai stage 0 - II without active disease according to IWCLL 2008 criteria
  3. Predicted time to first treatment of ≤3 years according to MDACC nomogram.
  4. ECOG performance status of 0-2
  5. Adequate hepatic function, defined as serum aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 1.5 x ULN except Gilbert's Syndrome where a direct bilirubin ≤ 1.5 ULN will be used.
  6. Adequate renal function, defined as an estimated creatinine clearance ≥30 mL/min using the Cockcroft-Gault equation
  7. Willingness to receive all outpatient treatment, all laboratory monitoring, and all radiological evaluations at the institution that administers study drug for the entire study
  8. Willingness of male and female patients, if sexually active, to use an effective barrier method of contraception during the study and for 3 months following the last dose of study drug
  9. Ability to provide written informed consent and to understand and comply with the requirements of the study

Exclusion Criteria

  1. Any investigational agent(s) within 4 weeks prior to entry
  2. Uncontrolled autoimmune hemolytic anemia (Hgb < 11g/deciliter) or idiopathic thrombocytopenic purpura (< 100,000/µl)
  3. Any previous treatment (chemotherapy, radiotherapy, and/or monoclonal antibodies) intended specifically to treat CLL
  4. Treatment with corticosteroids other than physiological replacement within the previous week or treatment with immunosuppressive medication within the previous week.
  5. Major surgery within 4 weeks prior to inclusion
  6. Currently active, clinically significant cardiovascular disease or a history of myocardial infarction within 6 months prior to inclusion
  7. Uncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibiotics
  8. Known history of infection with human immunodeficiency virus (HIV)
  9. Serologic status reflecting active hepatitis B or C infection.
  10. History of stroke or intracranial hemorrhage within 6 months prior to enrolment
  11. Current life-threatening illness, medical condition, or organ-system dysfunction that could compromise patient safety or put the study at risk
  12. Breast-feeding or pregnant women, or patients for whom there is a risk of conception and who are unable or unwilling to use appropriate contraception (for male and female patients up to 4 months after end of ibrutinib.)
  13. Previous malignancy with life expectancy less than 6 months or requiring systemic treatment (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
  14. Known drug abuse/ alcohol abuse
  15. Severe organ failures or diseases, including: clinically relevant coronary disease, myocardial infarction or any other relevant cardiovascular disorder within 12 months before study entry, severe psychiatric illness and severe infection.

Group 2: Ibrutinib treated patients

Inclusion Criteria

  1. Age ≥ 18 years old
  2. Males or females with CLL diagnosed according to IWCLL diagnostic criteria who have been treated with ibrutinib therapy for at least 12 months and have had no more than 1 other treatment for CLL prior to receiving ibrutinib.
  3. Currently in complete or partial remission (PR)/PR with lymphocytosis (PRL)
  4. MRD positivity defined as >1.0% CLL cells in the bone marrow by flow cytometry
  5. ECOG performance status of 0-2
  6. Adequate hepatic function, defined as serum aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 1.5 x ULN, unless Gilbert's Syndrome where a direct bilirubin ≤ 1.5 ULN will be used.
  7. Adequate renal function, defined as estimated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation
  8. Willingness to receive all outpatient treatment, all laboratory monitoring, and all radiological evaluations at the institution that administers study drug for the entire study
  9. Willingness of male and female patients, if sexually active, to use an effective barrier method of contraception during the study and for 3 months following the last dose of study drug
  10. Ability to provide written informed consent and to understand and comply with the requirements of the study

Exclusion Criteria

  1. Any investigational agent(s) within 4 weeks prior to entry
  2. Known involvement of the central nervous system by lymphoma or leukemia
  3. History or current evidence of Richter's transformation or prolymphocytic leukemia
  4. Uncontrolled autoimmune hemolytic anemia (Hgb < 11g/deciliter) or idiopathic thrombocytopenic purpura (< 100,000/µl)
  5. Any previous treatment (chemotherapy, radiotherapy, and/or monoclonal antibodies) intended specifically to treat CLL
  6. Corticosteroid use within 1 week prior to first dose of study drug, with the exception of inhaled, topical, or other local administrations. Patients requiring systemic steroids at daily doses > 20 mg prednisone (or corticosteroid equivalent), or those who are administered steroids for leukemia control or white blood cell (WBC)-count-lowering are excluded
  7. Major surgery within 4 weeks prior to inclusion
  8. Currently active, clinically significant cardiovascular disease or a history of myocardial infarction within 6 months prior to inclusion
  9. Uncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibiotics
  10. Known history of infection with human immunodeficiency virus (HIV)
  11. Serologic status reflecting active hepatitis B or C infection
  12. History of stroke or intracranial hemorrhage within 6 months prior to enrollment
  13. Current life-threatening illness, medical condition, or organ-system dysfunction that could compromise patient safety or put the study at risk
  14. Requirement for anticoagulation with warfarin, or for treatment with a strong CYP3A4/5 and/or CYP2D6 inhibitor
  15. Breast-feeding or pregnant women, or patients for whom there is a risk of conception and who are unable or unwilling to use appropriate contraception (for male and female patients up to 4 months after end of ibrutinib.)
  16. Previous malignancy with life expectancy less than 6 months or requiring systemic treatment (except colorectal cancer, history of basal cell or squamous carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
  17. Known drug abuse/ alcohol abuse
  18. Severe organ failures or diseases, including: clinically relevant coronary disease, myocardial infarction or any other relevant cardiovascular disorder within 12 months before study entry, severe psychiatric illness and severe infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03265717


Contacts
Layout table for location contacts
Contact: Valerie Doppler, MD +33671624138 valerie.doppler@invectys.com
Contact: Thierry Huet, PhD +33181800522 thierry.huet@invectys.com

Locations
Layout table for location information
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Philip Thompson, MD    713-794-1602    PAThompson2@mdanderson.org   
Sponsors and Collaborators
Invectys

Layout table for additonal information
Responsible Party: Invectys
ClinicalTrials.gov Identifier: NCT03265717     History of Changes
Other Study ID Numbers: INVAC1-CT-201
First Posted: August 29, 2017    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell